Research programme: antibody therapeutics - WuXi Biologics
Alternative Names: Neutralizing antibodies for 2019-nCoV - WuXi Biologics; Neutralizing antibodies for Coronavirus - WuXi BiologicsLatest Information Update: 28 Feb 2024
At a glance
- Originator WuXi Biologics
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
Development Overview
Introduction
Neutralising antibody therapeutics are being developed by WuXi Biologics for the treatment of COVID-2019 infections. WuXi Biologics is using is proprietary integrated technology platforms to develop these candidates. Early research is underway in China.
As at February 2024, no recent reports of development had been identified for research development in COVID-2019-infections in China (Parenteral).
Key Development Milestones
As of August 2020, WuXi Biologics filed three COVID-19 antibody IND filings [1] .
In January 2020, WuXi Biologics announced its intention to produce the first batch of antibodies for preclinical toxicology studies and initial human clinical studies in two months. The company also plans to complete all studies from DNA to IND within 4-5 months [2] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antibodies, Antivirals
- Target Virus internalisation
- Mechanism of Action Virus internalisation inhibitors
-
WHO ATC code
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (Research) | China | Parenteral / unspecified | WuXi Biologics | 28 Feb 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| WuXi Biologics | Originator | China |
| WuXi Biologics | Owner | China |
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 31 Dec 2020 | Trial Update | WuXi Biologics plans clinical trial for COVID-2019 infections in second half of 2020 [1] | 20 Aug 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Feb 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in China (Parenteral) Updated 28 Feb 2024 |
| 17 Aug 2020 | Regulatory Status | WuXi Biologics files IND application for COVID-2019 infections [1] Updated 20 Aug 2020 |
| 17 Aug 2020 | Trial Update | WuXi Biologics plans clinical trial for COVID-2019 infections in second half of 2020 [1] Updated 20 Aug 2020 |
| 28 Jan 2020 | Phase Change | Early research in COVID-2019-infections in China (Parenteral) [2] Updated 03 Feb 2020 |
| 28 Jan 2020 | Trial Update | WuXi Biologics plans a clinical trial for COVID-2019-infections [2] Updated 03 Feb 2020 |
| 28 Jan 2020 | Trial Update | WuXi Biologics plans preclinical toxicology studies for COVID-2019-infections [2] Updated 03 Feb 2020 |
References
-
WuXi Biologics Records Excellent Interim Results.
Media Release -
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG